image
Healthcare - Medical - Care Facilities - NASDAQ - US
$ 96.1
0.146 %
$ 3.15 B
Market Cap
35.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMED stock under the worst case scenario is HIDDEN Compared to the current market price of 96.1 USD, Amedisys, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMED stock under the base case scenario is HIDDEN Compared to the current market price of 96.1 USD, Amedisys, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMED stock under the best case scenario is HIDDEN Compared to the current market price of 96.1 USD, Amedisys, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMED

image
$98.0$98.0$97.0$97.0$96.0$96.0$95.0$95.0$94.0$94.0$93.0$93.0$92.0$92.0$91.0$91.0$90.0$90.0$89.0$89.020252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25
FINANCIALS
2.35 B REVENUE
5.01%
94.5 M OPERATING INCOME
-39.55%
38.2 M NET INCOME
491.53%
222 M OPERATING CASH FLOW
61.58%
-8.36 M INVESTING CASH FLOW
-23.85%
-48.9 M FINANCING CASH FLOW
44.10%
595 M REVENUE
-0.55%
43.4 M OPERATING INCOME
320.95%
61.8 M NET INCOME
346.76%
-3.69 M OPERATING CASH FLOW
-5.25%
-1.37 M INVESTING CASH FLOW
-7.34%
-13.3 M FINANCING CASH FLOW
-18.70%
Balance Sheet Amedisys, Inc.
image
Current Assets 632 M
Cash & Short-Term Investments 303 M
Receivables 306 M
Other Current Assets 22.6 M
Non-Current Assets 1.51 B
Long-Term Investments 0
PP&E 124 M
Other Non-Current Assets 1.38 B
14.18 %14.32 %5.78 %64.67 %Total Assets$2.1b
Current Liabilities 514 M
Accounts Payable 40 M
Short-Term Debt 63.9 M
Other Current Liabilities 411 M
Non-Current Liabilities 444 M
Long-Term Debt 339 M
Other Non-Current Liabilities 105 M
4.17 %6.66 %42.82 %35.39 %10.96 %Total Liabilities$958.7m
EFFICIENCY
Earnings Waterfall Amedisys, Inc.
image
Revenue 2.35 B
Cost Of Revenue 1.33 B
Gross Profit 1.02 B
Operating Expenses 923 M
Operating Income 94.5 M
Other Expenses 56.4 M
Net Income 38.2 M
3b3b2b2b2b2b1b1b500m500m002b(1b)1b(923m)95m(56m)38mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
43.34% GROSS MARGIN
43.34%
4.03% OPERATING MARGIN
4.03%
1.84% NET MARGIN
1.84%
3.81% ROE
3.81%
2.02% ROA
2.02%
2.48% ROIC
2.48%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amedisys, Inc.
image
300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 38.2 M
Depreciation & Amortization 60.5 M
Capital Expenditures -6.55 M
Stock-Based Compensation 30.6 M
Change in Working Capital 39.9 M
Others 56.3 M
Free Cash Flow 215 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amedisys, Inc.
image
Wall Street analysts predict an average 1-year price target for AMED of $106 , with forecasts ranging from a low of $85 to a high of $150 .
AMED Lowest Price Target Wall Street Target
85 USD -11.55%
AMED Average Price Target Wall Street Target
106 USD 10.68%
AMED Highest Price Target Wall Street Target
150 USD 56.09%
Price
Max Price Target
Min Price Target
Average Price Target
15015014014013013012012011011010010090908080Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Amedisys, Inc.
image
Sold
0-3 MONTHS
35.9 K USD 1
3-6 MONTHS
188 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why You Should Retain AMED Stock in Your Portfolio for Now Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry. zacks.com - 3 weeks ago
AMED or CHE: Which Is the Better Value Stock Right Now? Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 month ago
Are Medical Stocks Lagging Amedisys (AMED) This Year? Here is how Amedisys (AMED) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year. zacks.com - 1 month ago
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care. zacks.com - 2 months ago
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
Amedisys (AMED) Tops Q1 Earnings Estimates Amedisys (AMED) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.03 per share a year ago. zacks.com - 2 months ago
Amedisys Reports First Quarter 2025 Financial Results BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. globenewswire.com - 2 months ago
Amedisys (AMED) Earnings Expected to Grow: Should You Buy? Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report? Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? zacks.com - 3 months ago
Here's Why You Should Retain AMED Stock in Your Portfolio Now Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry. zacks.com - 3 months ago
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care. zacks.com - 4 months ago
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 4 months ago
8. Profile Summary

Amedisys, Inc. AMED

image
COUNTRY US
INDUSTRY Medical - Care Facilities
MARKET CAP $ 3.15 B
Dividend Yield 0.00%
Description Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Contact 3854 American Way, Baton Rouge, LA, 70816 https://www.amedisys.com
IPO Date Aug. 17, 1994
Employees 19000
Officers Mr. Scott G. Ginn CPA Executive Vice President, Chief Operating Officer & Chief Financial Officer Kendra Kimmons Vice President of Marketing & Communications & Media Relations Ms. Denise Bohnert Chief Compliance Officer Ms. Jennifer Guckert Griffin Chief Legal Officer & Corporate Secretary Mr. Nick Muscato Chief Strategy Officer Ms. Allyson Guidroz Chief Accounting Officer & Principal Accounting Officer Mr. Keith Blanchard Acting Chief Information Officer Mr. Richard M. Ashworth President, Chief Executive Officer & Director Mr. Pete Hartley Chief Technology Officer & Senior Vice President of Business Operations Systems Ms. Caitlin Franklin Acting Chief People Officer